<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"><url>
      <loc>https://www.targetedonc.com/view/does-pimicotinib-expand-options-in-tenosynovial-giant-cell-tumor-</loc>
      <lastmod>2026-11-19T15:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T15:30:00Z</news:publication_date>
        <news:title><![CDATA[Does Pimicotinib Expand Options in Tenosynovial Giant Cell Tumor?]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-removes-pcnsl-limitation-from-liso-cel-label</loc>
      <lastmod>2026-11-19T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-19T13:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Removes PCNSL Limitation From Liso-Cel Label]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/oncologists-weigh-age-and-drug-interactions-in-mhspc-treatment-selection</loc>
      <lastmod>2026-11-18T22:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T22:00:00Z</news:publication_date>
        <news:title><![CDATA[Oncologists Weigh Age and Drug Interactions in mHSPC Treatment Selection]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/alternating-pazopanib-and-bevacizumab-shows-promise-in-metastatic-ccrcc</loc>
      <lastmod>2026-11-18T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Alternating Pazopanib and Bevacizumab Shows Promise in Metastatic ccRCC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/extrapolating-female-data-male-breast-cancer</loc>
      <lastmod>2026-11-18T19:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T19:00:00Z</news:publication_date>
        <news:title><![CDATA[Treating Male Breast Cancer: Women’s Data Only Go So Far]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-fast-tracks-elticertinib-for-previously-treated-egfr-exon-20-nsclc</loc>
      <lastmod>2026-11-18T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/ateganosine-cemiplimab-third-line-nsclc-thio-101</loc>
      <lastmod>2026-11-18T16:30:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T16:30:00Z</news:publication_date>
        <news:title><![CDATA[Ateganosine Plus Cemiplimab Shows 88% Disease Control in Third-Line NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/serena-6-prompts-earlier-esr1-testing-in-breast-cancer</loc>
      <lastmod>2026-11-18T15:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T15:00:00Z</news:publication_date>
        <news:title><![CDATA[SERENA-6 Prompts Earlier ESR1 Testing in Breast Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/galinpepimut-s-regal-phase-3-overall-survival-aml</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/what-positive-origami-5-results-would-mean</loc>
      <lastmod>2026-11-18T13:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-18T13:00:00Z</news:publication_date>
        <news:title><![CDATA[What Positive OrigAMI-5 Results Would Mean]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/selinexor-combo-advances-in-myelofibrosis-fda-review</loc>
      <lastmod>2026-11-17T21:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T21:00:00Z</news:publication_date>
        <news:title><![CDATA[Selinexor Combo Advances in Myelofibrosis FDA Review]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/neladalkib-fda-approval-alk-positive-nsclc</loc>
      <lastmod>2026-11-18T13:43:00.000Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T19:03:26.761Z</news:publication_date>
        <news:title><![CDATA[FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/anito-cel-post-car-t-burden-neurotoxicity</loc>
      <lastmod>2026-11-17T18:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T18:00:00Z</news:publication_date>
        <news:title><![CDATA[Dr Frigault on Anito-Cel’s Potential to Reduce Post CAR T Burden]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/fda-fast-tracks-onvansertib-for-first-line-ras-mutated-mcrc</loc>
      <lastmod>2026-11-17T17:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T17:00:00Z</news:publication_date>
        <news:title><![CDATA[FDA Fast Tracks Onvansertib for First-Line RAS-Mutated mCRC]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/daraxonrasib-pancreatic-cancer-aguirre-ras-inhibitor</loc>
      <lastmod>2026-11-17T16:01:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:01:00Z</news:publication_date>
        <news:title><![CDATA[Dr Aguirre on Daraxonrasib Bringing RAS-Targeted Therapy to Pancreatic Cancer]]></news:title>
      </news:news>
	</url><url>
      <loc>https://www.targetedonc.com/view/lenvatinib-pembrolizumab-yields-40-month-os-in-pretreated-thymic-tumors</loc>
      <lastmod>2026-11-17T16:00:00Z</lastmod>
      <news:news>
      <news:publication>
        <news:name>Targeted Onc - Immunotherapy, Biomarkers, and Cancer Pathways</news:name>
        <news:language>en</news:language>
      </news:publication>
        <news:publication_date>2026-11-17T16:00:00Z</news:publication_date>
        <news:title><![CDATA[Lenvatinib/Pembrolizumab Yields 40-Month OS in Pretreated Thymic Tumors]]></news:title>
      </news:news>
	</url></urlset>